Biotech Stock Report

Propanc (OTC: PPCH)

Category: Uncategorised

Propanc Receives Investment to Initiate GLP Safety Toxicology Study for PRP

Propanc Receives Investment to Initiate GLP Safety Toxicology Study for PRP Set to Initiate Development and GMP manufacture of Finished Drug Product for First-In-Man Studies PR Newswire MELBOURNE, Australia, July 5, 2016 MELBOURNE, Australia, July 5, 2016 /PRNewswire/ — Propanc Health Group Corporation (OTCQB: PPCH) (“Propanc” or “the Company”), an emerging healthcare company focusing on development of new and proprietary treatments for cancer patients […] read more

Propanc Identifies Future Opportunities for PRP as Pharma Executives Look for New Breakthroughs

Propanc Identifies Future Opportunities for PRP as Pharma Executives Look for New Breakthroughs Growing Consensus the Most Effective Way to Beat Cancer is through a Combination of Drugs PR Newswire MELBOURNE, Australia, June 15, 2016 MELBOURNE, Australia, June 15, 2016 /PRNewswire/ — Propanc Health Group Corporation (OTCQB: PPCH) (“Propanc” or “the Company”), an emerging healthcare company focusing on development of new and proprietary […] read more

Propanc Engages Two Advisory Firms to Identify Strategic Partnering Opportunities

Propanc Engages Two Advisory Firms to Identify Strategic Partnering Opportunities Maxim Group LLC and Partner International Inc. to Initiate Licensing Discussions for the Company’s Lead Product, PRP PR Newswire MELBOURNE, Australia, May 31, 2016 MELBOURNE, Australia, May 31, 2016 /PRNewswire/ — Propanc Health Group Corporation (OTCQB: PPCH) (“Propanc” or “the Company”), an emerging healthcare company focusing […] read more

Propanc Conducts Successful Scientific Advice Meeting with the MHRA

Propanc Conducts Successful Scientific Advice Meeting with the MHRA The Company confirms Preclinical and Clinical Development Pathway for PRP PR Newswire MELBOURNE, Australia, May 2, 2016 MELBOURNE, Australia, May 2, 2016 /PRNewswire/ — Propanc Health Group Corporation (OTCQB: PPCH) (“Propanc” or “the Company”), an emerging healthcare company focusing on development of new and proprietary treatments for […] read more

Propanc Files Two More Patents Citing New Compositions of Proenzymes for Cancer Treatment

Company Prepares for Scientific Advice Meeting and Additional Upcoming Milestones PR Newswire MELBOURNE, Australia, April 19, 2016 MELBOURNE, Australia, April 19, 2016 /PRNewswire/ — Propanc Health Group Corporation (OTCQB: PPCH) (“Propanc” or “the Company”), an emerging healthcare company focusing on development of new and proprietary treatments for cancer patients suffering from solid tumors such as pancreatic, […] read more

SeeThruEquity Issues Update on Propanc Health Group Corp (OTCQB: PPCH), Highlighting Recent Financing

NEW YORK, NY / ACCESSWIRE / April 14, 2016 / SeeThruEquity, a leading independent equity research and corporate access firm focused on small-cap and micro-cap public companies, today announced it has issued an update on Propanc Health Group Corp (OTCQB: PPCH). The report is available here: PPCH April 2016 Update Note. SeeThruEquity is an approved […] read more

CEO to Discuss Plans for Future Growth at Head Office of CFSG1 Ltd, New York

MELBOURNE, Australia, March 29, 2016 /PRNewswire/ — Propanc Health Group Corporation (OTCQB: PPCH) (“Propanc” or “the Company”), an emerging healthcare company focusing on development of new and proprietary treatments for cancer patients suffering from solid tumors such as pancreatic, ovarian and colorectal cancers, today announced the Company’s Chief Executive Officer,James Nathanielsz, is set to visit […] read more

Propanc Receives $1.2 Million to Fast Track Animal Safety Studies, GMP Manufacturing and Preclinical Development for Lead Product, PRP

MELBOURNE, Australia, March 21, 2016 /PRNewswire/ — Propanc Health Group Corporation (OTCQB: PPCH) (“Propanc” or “the Company”), an emerging healthcare company focusing on development of new and proprietary treatments for cancer patients suffering from solid tumors such as pancreatic, ovarian and colorectal cancers, today announced the Company received $1.2 million from an institutional investor in […] read more

Technical Data Influencing the Market — Analyst Notes on Propanc Health Group, Rocky Mountain High Brands, Schneider Electric and Assa Abloy

NEW YORK, NY / ACCESSWIRE / March 16, 2016 / Moments ago, Trader’s Choice released new research updates concerning several important developing situations including the following equities: Propanc Health Group Corp.(OTC: PPCH), Rocky Mountain High Brands Inc. (OTC: RMHB), Schneider Electric SE(OTC: SBGSY) and Assa Abloy AB (OTC: ASAZY). Trader’s Choice has perfected the profitable […] read more

Analyzing the Price Movement – Analyst Research on Propanc Health Group, Medical Marijuana, Progressive Care and Kirkland Lake Gold

NEW YORK, NY / ACCESSWIRE / March 8, 2016 / Moments ago, Trader’s Choice released new research updates concerning several important developing situations including the following equities: Propanc Health Group Corp.(OTC: PPCH), Medical Marijuana Inc. (OTC: MJNA), Progressive Care Inc. (OTC: RXMD) and Kirkland Lake Gold Inc. (OTC: KGILF). Trader’s Choice has perfected the profitable […] read more

Propanc Health Group Corp. (OTCQB: PPCH) Developing New Cancer Treatments for Patients Suffering from Pancreatic and Colorectal Cancers

NEW YORK, NY / ACCESSWIRE / March 7, 2016 / Propanc Health Group Corp. (OTCQB: PPCH) is developing new cancer treatments for patients suffering from pancreatic and colorectal cancers. They have developed a formulation of anti-cancer compounds which exert a number of effects designed to control or prevent tumors from recurring and spreading throughout the […] read more

Propanc Discovers PRP Dramatically Suppresses Cancer Stem Cells

MELBOURNE, Australia, Feb. 4, 2016 /PRNewswire/ — Propanc Health Group Corporation (OTCQB: PPCH) (“Propanc” or “the Company”), an emerging healthcare company focusing on development of new and proprietary treatments for cancer patients suffering from pancreatic, ovarian and colorectal cancers, today announced the Company has filed a third patent regarding the use of its lead product, […] read more

Where Investors Are Going — Complementary Research on Sierra Resource Group, Propanc Health Group, US Highland and Linc Energy

On Friday, January 15, 2016, NASDAQ Composite ended at 4,488.42, down 2.74%; Dow Jones Industrial Average declined 2.39%, to finish the day at 15,988.08; and the S&P 500 closed at 1,880.33, down 2.16%. – Sierra Resource Group Inc.’s stock edged lower by 28.57% to close Friday’s session at USD 0.0010. The company’s shares oscillated between […] read more

Propanc Receives Additional $525,000 from Institutional Investor; Initiates Animal Safety Toxicology Studies for PRP

MELBOURNE, Australia, Jan. 13, 2016 /PRNewswire/ — Propanc Health Group Corporation (OTCQB: PPCH) (“Propanc” or “the Company”), an emerging healthcare company focusing on development of new and proprietary treatments for cancer patients suffering from pancreatic, ovarian and colorectal cancers, today announced the Company received a further $525,000 tranche from an institutional investor in order to […] read more

SeeThruEquity Issues Update on Propanc Health Group Highlighting Positive Pre-Clinical Study Results

NEW YORK, NY / ACCESSWIRE / November 24, 2015 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced it has initiated coverage of Propanc Health Group Corp.. (OTCQB: PPCH) with a Price Target of $1.52. The report is available here: PPCH Initiation Report. SeeThruEquity […] read more

Propanc Demonstrates Significant Anti-Tumor Efficacy in Pancreatic and Ovarian Cancer Preclinical Models; Files Patent Specifying New Therapeutic Target Dose Range

MELBOURNE, AUSTRALIA / ACCESSWIRE / November 17, 2015 / Propanc Health Group Corporation (OTCQB: PPCH) (“Propanc” or “the Company”), an emerging healthcare company focusing on development of new and proprietary treatments for cancer patients suffering from pancreatic and colorectal cancers, today announced the Company has achieved significant tumor growth inhibition in pancreatic and ovarian cancers […] read more

Propanc Secures $4M Financing to Complete Preclinical Animal Studies and Progress Company into Human Trials

MELBOURNE, AUSTRALIA / ACCESSWIRE / November 10, 2015 / Propanc Health Group Corporation (OTCQB: PPCH) (“Propanc” or “the Company”), an emerging healthcare company focusing on development of new and proprietary treatments for cancer patients suffering from pancreatic and colorectal cancers, today announced the Company has secured $4 million from an institutional investor in order to […] read more

Propanc Secures Financing to Complete Preclinical Animal Studies and Progress Company towards Human Trials; Updates on Progress and Plans

MELBOURNE, AUSTRALIA / ACCESSWIRE / October 1, 2015 / Propanc Health Group Corporation (OTCQB: PPCH) (“Propanc” or “the Company”), an emerging healthcare company focusing on development of new and proprietary treatments for cancer patients suffering from pancreatic and colorectal cancers, today announced a summary of current activities and recent achievements which will see the Company […] read more